A global leader in real-time continuous glucose monitoring (CGM) for people with diabetes has announced new clinical study outcomes that further demonstrate the benefits of CGM use.
At the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) held in Hamburg, Germany, Dexcom has offered more details about its expanding portfolio of automated insulin delivery offerings.
New results from the COMISAIR seven-year study show significant and continued reduction of HbA1c with the use of real-time CGM by people with type 1 diabetes.
Regardless of insulin delivery method, multiple daily injections or insulin pump therapy, real-time CGM has greater and statistically significant HbA1c reduction when compared to self-monitoring blood glucose over seven years.
The COMISAIR study also shows further substantial reduction in HbA1c when real-time CGM is connected to an automated insulin delivery system, specifically Tandem Control IQ.
In addition, the study showed high CGM adherence over seven years, regardless of insulin delivery method, 88.8 per cent for those using CGM and multiple daily injections and 91.9 per cent for those using CGM and AID.
With the latest data from the COMISAIR study reaffirming the effectiveness of AID in improving diabetes management, Dexcom continues to strengthen its position as the world’s most connected CGM system, announcing the Dexcom G7 CGM system will begin launching with the Tandem t:slim X2 insulin pump before the end of the year in the US and multiple markets across Europe and Asia-Pacific.
This news follows the recent launch of the Omnipod 5 Automated Insulin Delivery System connected to Dexcom G6 in the UK and Germany.
Jake Leach, Executive Vice President and Chief Operating Officer at Dexcom, said: “Dexcom is the undisputed leader in connectivity and has safely powered AID systems for more than one million years of cumulative patient use.
“We’ve prioritised connectivity for more than a decade, which means our CGM systems are optimised to seamlessly connect with insulin delivery and digital health partners of all kinds, giving users freedom of choice in their diabetes journey and making Dexcom the clear choice for AID.”